NONLINEAR ELIMINATION AND PROTEIN-BINDING OF PROBENECID

被引:31
|
作者
EMANUELSSON, BM [1 ]
BEERMANN, B [1 ]
PAALZOW, LK [1 ]
机构
[1] KAROLINSKA INST, HUDDINGE HOSP, DEPT MED, DIV CARDIOL, S-14186 HUDDINGE, SWEDEN
关键词
D O I
10.1007/BF00543976
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Six healthy volunteers were given probenecid 0.5, 1 and 2 g p.o. and 0.5 g i.v. The protein binding of probenecid at different concentrations in human plasma was estimated by equlibrium dialysis. The free fraction was found to increase nonlinearly with increasing total probenecid concentration, up to a maximum free fraction of 26%. The plasma concentration-time data after the oral doses were described by a non-compartment open model with first-order absorption and Michaelis-Menten elimination. The mean absorption rate constant 0.0072 min-1 was dose-independent, and the maximal rate of elimination (mean 1429 .mu.g/min) did not differ between doses whether calculated from the total or free concentrations. The Michaelis-Menten constant decreased significantly from 67.1 to 55.5 .mu.g/ml as the dose increased from 1 to 2 g, while the unbound Michaelis-Menten constant remained unchanged. The elimination of probenecid after the 0.5 g dose was in the linear region of the Michaelis-Menten elimination when calculated from the total and the free concentrations. The volume of distribution increased only slightly from 9.5 to 11.41 as the dose increased from 0.5 to 2 g, but the unbound volume of distribution decreased significantly from 164 to 991. Absorption was complete and was independent of the dose administered.
引用
收藏
页码:395 / 401
页数:7
相关论文
共 50 条
  • [41] RETINOBLASTOMA PROTEIN-BINDING PROPERTIES ARE DEPENDENT ON 4 CYSTEINE RESIDUES IN THE PROTEIN-BINDING POCKET
    STIRDIVANT, SM
    AHERN, JD
    OLIFF, A
    HEIMBROOK, DC
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1992, 267 (21) : 14846 - 14851
  • [42] INVESTIGATION OF THE PROTEIN-BINDING OF DRUGS BY CONTINUOUS ULTRAFILTRATION .6. PROTEIN-BINDING OF ACENOCOUMAROL
    REHSE, K
    EHLERT, K
    ARCHIV DER PHARMAZIE, 1985, 318 (06) : 573 - 574
  • [43] PROTEIN-BINDING OF CLONAZEPAM AND VALPROATE
    FERRY, DG
    MCQUEEN, EG
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1978, 5 (03) : 258 - 258
  • [44] PROTEIN-BINDING PROPERTIES OF PRAZOSIN
    HOBBS, DC
    TWOMEY, TM
    RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY, 1979, 25 (01): : 189 - 192
  • [45] PROTEIN-BINDING OF FUSIDIC ACID
    BANNATYNE, RM
    CHEUNG, R
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1982, 31 (02): : 159 - 161
  • [46] PROTEIN-BINDING OF ANTISTAPHYLOCOCCAL ANTIBIOTICS
    LACEY, RW
    BARR, KW
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1986, 17 (05) : 679 - 679
  • [47] INVESTIGATIONS ON DPH PROTEIN-BINDING
    HAASS, A
    PFLUGHAUPT, KW
    SCHUTZ, A
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1978, 302 : R64 - R64
  • [48] HEPATIC PROTEIN-BINDING OF FOLATE
    CORROCHER, R
    DESANDRE, G
    PACOR, ML
    HOFFBRAND, AV
    CLINICAL SCIENCE AND MOLECULAR MEDICINE, 1974, 46 (04): : 551 - 554
  • [49] LIDOCAINE PROTEIN-BINDING IN PREECLAMPSIA
    BOTTORFF, MB
    PIEPER, JA
    BOUCHER, BA
    HOON, TJ
    RAMANATHAN, J
    SIBAI, BM
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 31 (06) : 719 - 722
  • [50] G PROTEIN-BINDING RECEPTORS
    VASSART, G
    PATHOLOGIE BIOLOGIE, 1992, 40 (08): : 763 - 766